Breaking News Instant updates and real-time market news.

SBUX

Starbucks

$66.74

-0.15 (-0.22%)

16:28
11/30/18
11/30
16:28
11/30/18
16:28

Starbucks offers 'significant upside', saysTigress Financial

Tigress Financial analyst Ivan Feinseth kept his Buy rating on Starbucks, saying the stock continues to offer "significant upside" thanks to its "ongoing expansion in China" and investments in new growth initiatives. The analyst points to the company's most recent comps strength - the highest in 5 quarters - driven by strength in U.S. and Asian markets, as well as its efforts to re-accelerate growth in the U.S. Feinseth further cites Starbucks' efforts that include new technologies, loyalty program expansion, and e-commerce capabilities, along with its evening program featuring expanded food offerings and alcoholic beverages.

  • 04

    Dec

  • 13

    Dec

SBUX Starbucks
$66.74

-0.15 (-0.22%)

11/30/18
JEFF
11/30/18
NO CHANGE
Target $76
JEFF
Buy
Starbucks price target raised to $76 from $66 at Jefferies
Jefferies analyst Andy Barish raised his price target for Starbucks to $76 from $66 and reiterates a Buy rating on the shares. The stock closed yesterday up 6c to $66.88. The analyst says that despite investor fears about long-term unit growth and same-store-sales visibility, he is a believer in Starbucks' China business. He sees a "visible path" to development and sustained drivers with delivery, and estimates the country could generate revenue of $6.4B by fiscal year 2024. Starbucks should command a multiple of 14 times estimated 2020 EBITDA, in line with its recent historical average, Barish tells investors in a research note titled "Marching Onward in China; Buy for Attractive Global Total Returns." At the current valuation of 13 times EBITDA, he sees an "attractive" entry point.
11/12/18
11/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Argus with analyst John Staszak citing his expectations of "continued revenue growth and new store openings" for the company, forecasting 14% EPS growth and 15% in total returns over the next several years. 2. L Brands (LB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying while he is not calling for an imminent inflection in the business, he now sees L Brands as the next retail turnaround story poised for positive shift in the "narrative" as the company appears set to begin embracing change with an "all options on the table" mentality. 3. Armstrong World (AWI) upgraded to Neutral from Underperform at BofA/Merrill with analyst John Lovallo saying Armstrong World deserves a higher multiple following the spin-off of Armstrong Flooring in April 2016 and is positive on the company's capital deployment strategy including buybacks, a recently initiated dividend, and tuck-in M&A. 4. Michael Kors (KORS) upgraded to Market Perform from Underperform at Bernstein with analyst Jamie Merriman citing valuation. 5. Crocs (CROX) upgraded to Neutral from Negative at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
ARGS
11/12/18
UPGRADE
Target $79
ARGS
Buy
Starbucks upgraded to Buy at Argus on continued revenue growth view
As reported earlier, Argus analyst John Staszak upgraded Starbucks to Buy from Hold with a price target of $79. The analyst cites his expectations of "continued revenue growth and new store openings" for the company, forecasting 14% EPS growth and 15% in total returns over the next several years. Staszak is also positive on Starbucks' "ongoing stock buybacks and dividend hikes", raising his EPS target for FY19 to $2.84 from $2.80 while setting a FY20 EPS targat of $3.10.
11/12/18
OPCO
11/12/18
NO CHANGE
OPCO
Outperform
Alibaba Singles Day growth deceleration suggests weaker macro environment, says Oppenheimer
Oppenheimer analyst Jason Helfstein notes that Alibaba's (BABA) 2018 Singles Day annual growth dropped to +27% year over year versus +39% in 2017, which he believes suggests a weaker macro environment in China, on top of the law of large numbers. The analyst also highlights that Starbucks (SBUX) participated in Double 11 for the first time. Overall, Helfstein continues to see Alibaba's ecosystem evolving with new elements, namely New Retail, Local Services and Travel. Going forward, he expects GMV growth will become more reliant on the cooperation and synergies between different channels and services. The analyst has an Outperform rating on Alibaba's shares.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

09:33
11/13/19
11/13
09:33
11/13/19
09:33
General news
Powell says 'noteworthy risks' to baseline economic outlook remain »

Federal Reserve Chairman…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$89.00

6.3 (7.62%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Recommendations
Tyson Foods analyst commentary  »

Tyson Foods price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$9.96

0.13 (1.32%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Conference/Events
eXp World Holdings management to meet with DA Davidson »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

TRPX

Therapix Biosciences

$1.41

-0.16 (-10.19%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Hot Stocks
Therapix Biosciences says Phase IIa study of THX-110 met primary endpoint »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$255.29

-0.7 (-0.27%)

09:31
11/13/19
11/13
09:31
11/13/19
09:31
Conference/Events
House Science, Space & Technology Committee to hold a hearing »

The Subcommittee on Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EEFT

Euronet

$149.96

1.99 (1.34%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Conference/Events
Euronet management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DG

Dollar General

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Recommendations
Dollar General analyst commentary  »

Dollar General Q3 comp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

BGNE

BeiGene

$196.20

4.5 (2.35%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Downgrade
BeiGene rating change  »

BeiGene downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

DEO

Diageo

$157.94

-1.87 (-1.17%)

09:29
11/13/19
11/13
09:29
11/13/19
09:29
Conference/Events
Diageo management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DBD

Diebold

$8.10

0.025 (0.31%)

09:28
11/13/19
11/13
09:28
11/13/19
09:28
Conference/Events
Diebold management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPX

Continental Building

$35.76

3.73 (11.65%)

, GMS

GMS Inc.

$30.73

0.21 (0.69%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Recommendations
Continental Building, GMS Inc., Foundation Building Materials analyst commentary  »

Continental Building…

CBPX

Continental Building

$35.76

3.73 (11.65%)

GMS

GMS Inc.

$30.73

0.21 (0.69%)

FBM

Foundation Building Materials

$21.20

0.2 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRLBF

Cresco Labs

$0.00

(0.00%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Conference/Events
Cresco Labs management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNI

Canadian National

$93.08

-0.485 (-0.52%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
Canadian National management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 21

    Nov

  • 22

    Nov

BRTX

BioRestorative Therapies

$0.00

(0.00%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
BioRestorative Therapies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TLRY

Tilray

$21.57

-0.4 (-1.82%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Recommendations
Tilray analyst commentary  »

Tilray price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/13/19
11/13
09:25
11/13/19
09:25
General news
Fed Chair Powell goes to Capitol Hill for his JEC testimony »

Fed Chair Powell goes to…

EL

Estee Lauder

$187.89

0.63 (0.34%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 06

    Feb

BWEN

Broadwind Energy

$1.53

(0.00%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Conference/Events
Broadwind Energy management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

BLDR

Builders FirstSource

$24.75

0.4 (1.64%)

09:22
11/13/19
11/13
09:22
11/13/19
09:22
Conference/Events
Builders FirstSource management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 05

    Dec

NVFY

Nova Lifestyle

$0.54

(0.00%)

09:21
11/13/19
11/13
09:21
11/13/19
09:21
Earnings
Nova Lifestyle reports Q3 revenue $9.3M vs. $16.7M last year »

Tawny Lam, Chairperson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMN

AMN Healthcare

$60.42

0.53 (0.88%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Conference/Events
AMN Healthcare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PHOT

GrowLife

$0.00

(0.00%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Earnings
GrowLife reports Q3 revenue $2.3M vs. $1M last year »

GrowLife CEO Marco Hegyi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$28.32

-0.45 (-1.56%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Conference/Events
Aimmune management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Hot Stocks
Neoleukin Therapeutics expects cash to fund operations through 2021 »

Cash and cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:18
11/13/19
11/13
09:18
11/13/19
09:18
Earnings
Neoleukin Therapeutics reports Q3 EPS ($2.26), one est. (4c) »

"The past quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.